Wearable AI Heart Sound Monitoring Patch HeartSound Receives FDA Approval: 14-Day Early Warning for Heart Failure Deterioration
Eko Health's AI heart sound monitoring patch HeartSound receives FDA 510(k) approval, detecting heart failure deterioration an average of 14 days in advance through continuous heart sound monitoring.
US cardiac monitoring company Eko Health announced on May 29, 2029 that its AI heart sound monitoring patch HeartSound received FDA 510(k) clearance. The patch, just 5cm x 3cm in size, adheres to the chest for continuous heart sound monitoring, with AI algorithms alerting users an average of 14 days before heart failure deterioration.
HeartSound incorporates a high-sensitivity piezoelectric sensor sampling 1,000 heart sound data points per second. The device's edge AI chip completes heart sound analysis locally, uploading only anomalous data to the cloud. In a clinical trial involving 3,200 heart failure patients, HeartSound achieved 91% sensitivity in deterioration alerts with only 8% false positive rate.
The American Heart Association stated that HeartSound represents cardiac monitoring's shift from "passive recording" to "active prediction." The device's monthly lease is $99 and has been included in the Medicare reimbursement catalog.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.